Harrow has announced the re-launch of Verkazia (cyclosporine ophthalmic emulsion 0.1%), a treatment for vernal keratoconjunctivitis (VKC). The re-launch will improve access to a therapy that addresses the underlying inflammatory mechanisms of VKC while reducing reliance on topical corticosteroids, the company said in a press release.

VKC is a chronic disease characterized by persistent ocular inflammation that can lead to severe itching, photophobia, pain, tearing, and, in some cases, corneal damage. The disease often begins in childhood and may persist through adolescence or into adulthood. Although antihistamines are typically used as first-line therapy, many patients remain inadequately controlled, leading clinicians to consider corticosteroids, which carry risks including glaucoma and cataract formation with long-term use.

Verkazia is a topical calcineurin inhibitor immunomodulator that was originally developed by Santen Pharmaceutical and received US Food and Drug Administration (FDA) approval in 2021 for the treatment of VKC. Following Santen’s decision to divest certain US ophthalmic assets in 2023, Harrow acquired commercial rights to Verkazia. During the transition, the product experienced a period of limited availability in the United States. Harrow said the relaunch is intended to restore consistent access to the therapy through initiatives focused on supply, affordability, and physician education. OM